Stockscreener 앱 받기
26.52
1.08%
-0.29
시간 외 거래:
26.52
전일 마감가:
$26.81
열려 있는:
$26.86
하루 거래량:
689.29K
Relative Volume:
1.17
시가총액:
$1.90B
수익:
$81.26M
순이익/손실:
$-102.66M
주가수익비율:
-19.39
EPS:
-1.3678
순현금흐름:
$-77.62M
1주 성능:
-0.19%
1개월 성능:
-3.46%
6개월 성능:
+9.45%
1년 성능:
+64.11%
1일 변동 폭
$26.23
$26.88
1주일 범위
$26.14
$27.89
52주 변동 폭
$16.00
$31.34
Zymeworks Inc. Stock (ZYME) Company Profile
명칭
Zymeworks Inc.
전화
604-678-1388
주소
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
26.52 | 1.90B | 81.26M | -102.66M | -77.62M | -1.3678 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-10-24 | 재개 | Wells Fargo | Equal Weight |
| 2025-10-14 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | TD Cowen | Buy |
| 2024-12-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-07 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | 재개 | Wells Fargo | Overweight |
| 2023-01-04 | 재확인 | H.C. Wainwright | Neutral |
| 2022-12-20 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | 재개 | Wells Fargo | Overweight |
| 2022-05-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-03-15 | 개시 | Evercore ISI | Outperform |
| 2021-12-10 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | 재개 | Guggenheim | Neutral |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-02-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | 재개 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-08-06 | 개시 | SVB Leerink | Outperform |
| 2020-01-10 | 개시 | Wolfe Research | Outperform |
| 2019-12-09 | 개시 | JP Morgan | Neutral |
| 2019-11-25 | 개시 | H.C. Wainwright | Buy |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-09-30 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | 개시 | Stifel | Buy |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-05-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-03-19 | 개시 | Raymond James | Outperform |
모두보기
Zymeworks Inc. 주식(ZYME)의 최신 뉴스
Theravance Biopharma Insider Brett Grimaud Reports Complete Share Cancellation Following Zymeworks Merger - Kalkine Media
Vancouver biotech Zymeworks closes US$929M Theravance deal - Business in Vancouver
Zymeworks Inc. (ZYME) Stock Price, News, Quote & History - Yahoo! Finance Canada
Zymeworks closes out acquisition of Theravance for USD 929m - AllSci
What Does the Theravance Acquisition Add for Zymeworks (NASDAQ:ZYME)? - Kalkine Media
Zymeworks Completes Acquisition of Theravance Biopharma - Indovizka.com
Zymeworks Finalizes Merger with Theravance Biopharma and Launches $350M Senior Secured Notes - Kalkine Media
Zymeworks completes acquisition of Theravance Biopharma By Investing.com - Investing.com Canada
Zymeworks completes acquisition of Theravance Biopharma - Investing.com
Zymeworks Raises $350 Million Notes and Launches Ampreloxetine CVR - TradingView
A $350 million debt issue helped fund Zymeworks (ZYME)'s Theravance acquisition, with cash due per eligible share. - Stock Titan
Squarepoint Ops LLC Reduces Holdings in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks stock gains on fresh Wolfe Research coverage - AD HOC NEWS
Zymeworks stock gains on merger approval and a $41 target - AD HOC NEWS
Zymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Theravance Biopharma Shareholders Endorse Merger with Zymeworks Inc. - kalkinemedia.com
Zymeworks Stock Price Forecast. Should You Buy ZYME? - StockInvest.us
Theravance Biopharma shareholders approve merger with Zymeworks - Investing.com
Theravance Biopharma shareholders approve merger with Zymeworks By Investing.com - Investing.com UK
Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow (NASDAQ:ZYME) - Seeking Alpha
Zymeworks stock gains as Theravance deal and valuation draw investor focus - AD HOC NEWS
Zymeworks Inc. (ZYME): Investor Outlook Reveals 50% Upside Potential In Biotech Arena - DirectorsTalk Interviews
Why Is Wolfe Research Starting Coverage On Zymeworks (NASDAQ:ZYME)? - Kalkine Media
Wolfe Research Begins Coverage on Zymeworks (NASDAQ:ZYME) - MarketBeat
Zymeworks Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 238,026 Shares of Zymeworks Inc. $ZYME - MarketBeat
Wellington Management Group LLP Takes $2.88 Million Position in Zymeworks Inc. $ZYME - MarketBeat
Legal & General Group Plc Makes New $1.13 Million Investment in Zymeworks Inc. $ZYME - MarketBeat
Bank of New York Mellon Corp Acquires New Holdings in Zymeworks Inc. $ZYME - MarketBeat
JPMorgan Chase & Co. Boosts Zymeworks (NASDAQ:ZYME) Price Target to $33.00 - MarketBeat
Zymeworks (ZYME) Falls 3.7% to $29.9 as Shares Slip Below $30RVOL Breakout - careplusvn.com
Zymeworks (NASDAQ:ZYME) Hits New 1-Year HighTime to Buy? - MarketBeat
Zymeworks stock hits 52-week high at 30.75 USD - Investing.com
Zymeworks stock hits 52-week high at 30.75 USD By Investing.com - Investing.com Nigeria
ZJM stock holds near its latest trade. Zymeworks data still drives the setup - AD HOC NEWS
Enterprise value to revenue forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView
Man Group plc Invests $5.51 Million in Zymeworks Inc. $ZYME - marketbeat.com
4,251,030 Shares in Zymeworks Inc. $ZYME Bought by BlackRock Inc. - marketbeat.com
Zymeworks stock holds near $28.27 as market cap tops $2.01 billion - ad-hoc-news.de
FY2026 EPS Estimates for Zymeworks Raised by HC Wainwright - MarketBeat
Is Zymeworks (ZYME) Stock Fully Priced After Its 301% Run? - Yahoo Finance
Zymeworks shifts to revenue growth after FDA ap... - Pluang
HC Wainwright Has Strong Estimate for Zymeworks Q3 Earnings - marketbeat.com
Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval - Seeking Alpha
Zymeworks moves higher as Street cheers Ziihera regimen approval - Seeking Alpha
Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens - Sahm
Zymeworks stock hits 52-week high at 29.81 USD By Investing.com - Investing.com South Africa
Zymeworks stock rating reiterated at Market Outperform by Citizens - Investing.com India
Zymeworks Announces FDA Approval of Ziihera-Based Regimens for First-Line HER2-Positive Gastroesophageal Adenocarcinoma and $250 Million Milestone Payment from Jazz Pharmaceuticals - quiverquant.com
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma - NTB Kommunikasjon
Zymeworks Shares Rise Ahead of Key FDA Decision on Zanidatamab - Yahoo Finance
Zymeworks Inc. (ZYME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):